Marc Mugmon, MD, is Director of Medical Telemetry at MedStar Union Memorial Hospital (MUMH) and a clinical cardiologist at MedStar Chesapeake CardioVascular Associates in Baltimore. In addition, he is a Clinical Assistant Professor of Medicine at the University of Maryland School of Medicine in Baltimore.
Dr. Mugmon specializes in general clinical and preventive cardiology. At MUMH, he serves on the Code Committee. He is a fellow of the American College of Cardiology (ACC), the American College of Physicians, and the American Heart Association (AHA), and he is a member of the AHA Council on Clinical Cardiology. Dr. Mugmon is active in the ACC's Maryland chapter, currently serving as its President and as a member of its Executive Council. His research has been published in peer-reviewed journals, including the American Journal of Cardiology and the American Heart Journal. He serves on the editorial board of the Journal of Community Hospital Internal Medical Perspectives. Dr. Mugmon is fluent in English and French.
Dr. Mugmon received his medical degree from the George Washington University School of Medicine, Washington, DC. He continued his training with a medical residency at the University of Maryland Hospital in Baltimore, followed by a cardiology fellowship at the Baltimore Veterans Administration Medical Center.
Dr. Mugmon's research interests include
- General clinical cardiology
- Preventive cardiology
- Cardiac drug trials
- Cardiovascular disease
A Study of SCH 530348 in Addition to Standard Care in Patients with Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2ºP - TIMI 50)
Dr. Mugmon was a principal investigator on this study, sponsored by Schering-Plough. This study was designed to determine whether the addition of SCH 530348 to standard care would help prevent heart attacks and stroke in patients with a history of atherosclerosis. This study also assessed risk of bleeding with SCH 530348.
Prospective Randomized Evaluation of Celecoxib vs. Ibuprofen or Naproxen
Dr. Mugmon is a principal investigator on this study, sponsored by Pfizer. This study was designed to compare the risks and benefits of celecoxib vs. ibuprofen or naproxen in patients with rheumatoid arthritis who have or are at high risk for cardiovascular disease.
- Research Areas